Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, prospective, exploratory clinical study aiming to evaluate the efficacy
and safety profile of sintilimab combined with anlotinib hydrochloride and
platinum-containing dual-agent chemotherapy regimens in advanced or metastatic NSCLC as
first-line treatment. Totally 40 patients with negative driver genes (20 patients of squamous
cell carcinoma, 20 patients of non-squamous cell carcinoma) are to be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University